Clinical trials provide far more information than just the safety and efficacy of a treatment. Information about the natural course and the risk factors of the disease can be gathered. Of equal importance is the collaboration of clinical investigators as they develop and carry out protocols facilitates incorporation of new ideas into medical practice.
Adjuvant use of bromfenac ophthalmic solution 0.09% (Xibrom, ISTA Pharmaceuticals) with ranibizumab (Lucentis, Genentech) reduced the reduced the number of ranibizumab injections needed to control choroidal neovascularization secondary to age-related macular degeneration. Use of the two drugs together resulted in better visual acuity outcomes than those achieved with ranibizumab alone.
A prismatic IOL (P-Flex, Rayner) is giving hope to patients with advanced age-related macular degeneration because of its novel design. A Fresnel prism in the IOL reflects images onto healthy retinas in patients with small macular lesions. No scotoma or diplopia has resulted from implantation of this IOL in two patients.
Micropulse laser trabeculoplasty (MLT) using a specific diode laser seems to be a safe and effective approach to performing trabeculoplasty.
A proprietary miniature glaucoma device implanted under a partial-thickness scleral flap is safe and predictable compared with trabeculectomy.
Wavefront-guided spectacles may provide a better solution than standard eyeglasses for patients with subjective complaints stemming from higher-order aberrations after LASIK.
Analysis programs for longitudinal assessment of glaucoma are advancing. A new optical coherence tomography software analysis program provides overlays of the retinal nerve fiber layer (RNFL) thickness plots as well as regression
A proprietary retina tomograph (Heidelberg Retina Tomograph 3, Heidelberg Engineering) can help ophthalmologists differentiate patients at risk of progression to glaucoma from those patients who are not, based on structural and functional findings in the optic nerve and visual fields.
A better visual outcome can be achieved after corneal transplantation surgery in pediatric patients with Peters' anomaly type 1 if the surgery is performed when the patients are aged approximately 10 to 15 weeks and if the glaucoma and astigmatism are well controlled.
Monocyte chemoattractant protein 1 (MCP-1) seems to be responsible for apoptosis of the photoreceptors in certain visual disorders. MCP-1 seems to have a critical role in mediating photoreceptor apoptosis after retinal detachment in an experimental murine model. Specifically, MCP-1 causes macrophages and microglia to accumulate and generate oxidative stress in the retina.